The management of incidental findings of reduction mammoplasty specimens

Abstract

French

Reduction mammoplasty is one of the most commonly performed procedures in plastic surgery. Occasionally, there are findings reported by pathologists that are unfamiliar to the treating surgeon. The aim of the present study was to determine the types of pathologies encountered in reduction mammoplasty specimens. From this list of diagnoses, a best practice guideline for management will be organized to better assist plastic surgeons in the management of patients with incidental findings on pathology reports. A total of 441 pathology reports from patients who underwent bilateral or unilateral reduction mammoplasty in the past three years were identified. A list of 21 different pathologies was generated from the pathology reports, along with supplemental data from recent texts and articles. Occult carcinomas were encountered in two cases (0.45%) and high-risk lesions were found in three cases (0.68%) at the authors' institution. An algorithm was then constructed to organize the pathologies according to risk of malignancy and assign them to a management guideline. There are many different lesions encountered incidentally in reduction mammoplasty specimens that may or may not confer some cancer risk. It is important for plastic surgeons to know which lesions need closer follow-up to provide the best care for their patients.

Keywords

Breast Incidental Mammoplasty Pathology Reduction Specimen

Get full access to this article

View all access options for this article.

References

American Society of Plastic Surgeons. <www.plasticsurgery.org/reconstructive-procedures/breast-reduction.html?sub=Breast%20reduction%20surgery:%20health%20and%20beauty%20for%20life#content> (Accessed September 1, 2013).

Singh

Losken

. Additional benefits of reduction mammaplasty: A systematic review of the literature. Plast Reconstr Surg 2012; 129: 562–70.

Ishag

Bashinsky

Beliaeva IV Niemann

Marsh

Jr . Pathologic findings in reduction mammaplasty specimens. Am J Clin Pathol 2003; 120: 377–80.

United States Centers for Disease Control and Prevention. July 22, 2013. <www.cdc.gov/vitalsigns/breastcancer/> (Accessed September 2, 2013).

Cook

Fuller

. Does histopathological examination of breast reduction specimens affect patient management and clinical follow up? J Clin Pathol 2004; 57: 286–9.

Hruban

Isacso

Phelps

Westra

. Surgical Pathology Dissection: An Illustrated Guide, 2nd edn. New York: Springer-Verlag, 2003; 138–40.

Tafra,

Lorraine

. Management of benign breast lesions. In: Babiera

Skoracki

Esteva

, eds. Advanced Therapy of Breast Disease. Shelton: People's Medical House, 2012; 339–51.

Piana de Andrade Victor

King

Tari

. Management of high risk breast lesions. In: Babiera

Skoracki

Esteva

, eds. Advanced Therapy of Breast Disease. Shelton: People's Medical House, 2012; 353–72.

Fitzgibbons

Henson

Hutter

. Benign breast changes and the risk for subsequent breast cancer: An update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998; 122: 1053–5.

10.

Freedman

Smith

Estabrook

Balderacchi

Tartter

. Incidence of occult carcinoma and high-risk lesions in mammaplasty specimens. Int J Breast Cancer 2012; 145630.

11.

Rai

Mahabir

Roberts

Song

Hamid

White

IV . Contralateral prophylactic mastectomy. Ann Plastic Surg 2011; 67: 215–9.

12.

Clark

Whang

Paige

. Incidence of precancerous lesions in breast reduction tissue: A pathologic review of 562 consecutive patients. Plast Reconstruct Surg 2009; 124: 1033–9.

13.

Kyriopoulos

Kakagia

Zapandioti

Papaliodi

Tsoutsos

. Pathologic findings in breast reduction specimens: Detection of occult premalignant and cancerous lesions. Onkologie 2012; 35: 583–6.

14.

Hruban

Isacso

Phelps

Westra

. Surgical Pathology Dissection: An Illustrated Guide, 2nd edn. New York: Springer-Verlag, 2003; 138–140.

15.

National Accreditation Program for Breast Centers. Revised April 14, 2013. <http://napbc-breast.org/standards/standards.html> (Accessed October 8, 2013).

16.

National Comprehensive Cancer Network. Revised 2011. <www.nccn.org/professionals/physician_gls/f_guidelines.asp#site> (Accessed October 8, 2013).